15:59 , Feb 6, 2019 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Fruit fly studies suggest promoting BMPRI or BMP7 expression could help treat ALS. In a Drosophila model of ALS expressing mutant SOD1, overexpression of the Drosophila ortholog of human BMPRI...
22:24 , Jan 5, 2018 |  BioCentury  |  Finance

Scholar goes to the clinic

While Scholar Rock LLC’s series C round will bring the biotech’s lead program into the clinic, investors also want continued investment in the company’s growth factor modulation platform to maximize its value. On Jan. 3,...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Ember Therapeutics, Knight Therapeutics deal

Ember granted Knight exclusive rights to commercialize Ember’s bone morphogenetic protein 7 ( BMP7 ; OP-1) pipeline in Canada, Israel, Russia and sub-Saharan Africa. The lead product has completed a Phase IIa trial to treat...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Company News

Ember Therapeutics, Mariel deal

Obesity and diabetes company Ember and Mariel, which is developing compounds targeting bone morphogenetic protein 7 ( BMP7 ; OP-1), will merge and form Ember Therapeutics Inc. The companies did not disclose financial terms and...
07:00 , Mar 10, 2014 |  BC Week In Review  |  Company News

Olympus Corp. musculoskeletal news

Olympus said it will discontinue operations for its U.S. biotechnology division, Olympus Biotech Corp. , which includes a facility in Hopkinton, Mass. Olympus said it made the decision for financial reasons. Olympus Biotech will discontinue...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Clinical News

NeoStem preclinical data

In severe combined immunodeficiency disease (SCID) mice with surgically-induced cranial defects, G-CSF mobilized VSELs isolated from the blood of healthy human donors and transplanted into the defects using collagen sponge scaffolds significantly increased tissue mineral...
07:00 , Oct 11, 2012 |  BC Innovations  |  Cover Story

Ember: warming up to brown fat

A team led by Boston-area researchers has shown that inhibiting a cation channel dubbed TRPV4 induced white fat cells to behave like brown fat, thereby protecting mice from diet-induced obesity and insulin resistance. 1 Ember...
07:00 , Jul 26, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Sheep model for load-bearing long bone defects Aged sheep with defects in their long bones could be useful for evaluating bone repair and regeneration treatments....
07:00 , May 31, 2012 |  BC Innovations  |  Targets & Mechanisms

Going to BAT

Two teams are reporting new targets for inducing the conversion of white fat to a brown-like phenotype, or boosting the activity of existing brown fat, that could help treat obesity and related metabolic diseases. A...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

Ember Therapeutics, Joslin Diabetes Center deal

The center granted Ember Therapeutics exclusive, worldwide rights to IP covering bone morphogenetic protein 7 ( BMP7 ; OP-1). The company said BMP7 has been shown to play a role in the regulation of brown...